Immunotherapy and Precision Medicine: Personalizing the Immune Response
Introduction
Over the past decade, immunotherapy has reshaped the therapeutic landscape of oncology. Unlike conventional cancer treatments such as cytotoxic chemotherapy or radiation which primarily target rapidly dividing cells immunotherapy aims to harness the patient’s immune system to recognize and eliminate malignant cells. Among the most significant advances in this field has been the development of immune checkpoint inhibitors, which restore antitumor immune responses by blocking inhibitory signaling pathways that suppress T-cell activity.
Checkpoint inhibitors targeting programmed cell death protein 1 (PD-1), its ligand PD-L1, and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) have demonstrated clinical efficacy across multiple malignancies, including melanoma, non-small cell lung cancer (NSCLC), renal cell carcinoma, and certain gastrointestinal cancers. These therapies have produced durable responses in some patients, including cases where conventional treatments had limited effectiveness.
However, immunotherapy does not benefit all patients. Clinical trials have shown that response rates to checkpoint inhibitors often range between 15% and 40% depending on tumor type, with substantial variability in treatment outcomes. This heterogeneity has highlighted the importance of precision medicine approaches that identify which patients are most likely to respond to immunotherapy.
Advances in molecular diagnostics and tumor profiling have enabled researchers to identify several biomarkers associated with immunotherapy response. These biomarkers including PD-L1 expression, tumor mutational burden (TMB), and microsatellite instability (MSI) have become central to the development of personalized immunotherapy strategies. Understanding how these biomarkers influence treatment response is increasingly important for clinicians, researchers, and healthcare leaders involved in precision oncology.
Immune Checkpoint Inhibitors and the Immune Response
The immune system continuously monitors tissues for abnormal or malignant cells through mechanisms known as immune surveillance. Cytotoxic T lymphocytes recognize tumor-associated antigens presented on the surface of cancer cells and can initiate immune-mediated destruction.
Tumors, however, often evolve mechanisms that suppress immune responses and evade immune detection. One important mechanism involves the activation of immune checkpoint pathways. These pathways normally function to prevent excessive immune activation and protect healthy tissues from autoimmune damage. Cancer cells can exploit these pathways to inhibit antitumor immunity.
The PD-1/PD-L1 pathway represents one of the most widely studied checkpoint mechanisms. PD-1 is a receptor expressed on activated T cells, while PD-L1 is expressed on tumor cells and immune cells within the tumor microenvironment. When PD-1 binds to PD-L1, T-cell activity is suppressed, reducing the immune system’s ability to attack cancer cells.
Immune checkpoint inhibitors disrupt this interaction. Monoclonal antibodies targeting PD-1 or PD-L1 prevent the inhibitory signal, thereby restoring T-cell activity against tumor cells. Similarly, CTLA-4 inhibitors enhance immune responses by blocking inhibitory signals during early T-cell activation.
Although these therapies can produce durable tumor regression in some patients, their efficacy depends on complex interactions between tumor biology, immune signaling, and the tumor microenvironment. This complexity underscores the need for molecular biomarkers that can guide treatment selection.
Key Biomarkers in Immunotherapy
PD-L1 Expression
One of the earliest and most widely used biomarkers for predicting response to immune checkpoint inhibitors is PD-L1 expression within tumor tissues. PD-L1 can be detected using immunohistochemistry (IHC) assays, which measure the proportion of tumor cells or immune cells expressing the ligand.
Clinical trials in non-small cell lung cancer demonstrated that patients with higher levels of PD-L1 expression were more likely to respond to PD-1 or PD-L1 inhibitors. As a result, PD-L1 testing has become a routine diagnostic tool in many cancer treatment guidelines.
However, PD-L1 expression has important limitations as a predictive biomarker. Expression levels may vary across tumor regions and can change over time in response to therapy or tumor evolution. Furthermore, some patients with low or absent PD-L1 expression still respond to checkpoint inhibitors, while others with high expression fail to respond.
These limitations highlight the complexity of tumor-immune interactions and suggest that PD-L1 expression alone may not fully capture the biological determinants of immunotherapy response.
Tumor Mutational Burden
Tumor mutational burden (TMB) refers to the total number of somatic mutations present within a tumor genome. Tumors with high mutation rates often produce a greater number of abnormal proteins, known as neoantigens, which can be recognized by the immune system as foreign.
Several studies have demonstrated associations between high TMB and improved responses to checkpoint inhibitors. For example, cancers with elevated mutation rates such as melanoma and smoking-related lung cancers often exhibit greater sensitivity to immunotherapy.
The rationale underlying TMB as a biomarker is that tumors with higher numbers of mutations generate more neoantigens, increasing the likelihood that immune cells will recognize and target malignant cells.
Despite its promise, TMB measurement presents technical and methodological challenges. Different sequencing platforms and computational algorithms may produce varying estimates of mutational burden, complicating the interpretation of results across institutions. Efforts are ongoing to standardize TMB measurement and define clinically meaningful thresholds.
Microsatellite Instability
Another important biomarker in immunotherapy is microsatellite instability (MSI). Microsatellites are short, repetitive DNA sequences scattered throughout the genome. In normal cells, DNA mismatch repair (MMR) proteins maintain stability in these regions during DNA replication.
Defects in the mismatch repair system lead to microsatellite instability, resulting in high mutation rates across the genome. Tumors with high MSI (MSI-H) often accumulate numerous mutations and generate a large number of neoantigens.
Clinical studies have shown that MSI-H tumors respond particularly well to immune checkpoint inhibitors. In recognition of this finding, the U.S. Food and Drug Administration approved pembrolizumab in 2017 for the treatment of any solid tumor exhibiting MSI-H or mismatch repair deficiency, regardless of tumor origin. This represented one of the first tumor-agnostic approvals in oncology, reflecting the growing importance of molecular biomarkers in treatment selection.
MSI testing is now widely used in colorectal cancer and several other malignancies to identify patients who may benefit from immunotherapy.
Patient Selection: Why Immunotherapy Works for Some Patients
Despite major advances in immunotherapy, predicting which patients will benefit remains a central challenge in precision oncology. Multiple factors influence treatment response, including tumor genetics, immune cell infiltration, and characteristics of the tumor microenvironment.
Tumors that are immunologically “hot” meaning they contain significant infiltration of activated T cells are generally more responsive to checkpoint inhibitors. In contrast, “cold” tumors lacking immune infiltration may not respond effectively because the immune system has not recognized the tumor as a target.
Several biological factors contribute to these differences:
Neoantigen load: Tumors with more mutations may generate more recognizable antigens.
Tumor microenvironment: Immunosuppressive cells, such as regulatory T cells or myeloid-derived suppressor cells, may inhibit immune responses.
Antigen presentation pathways: Mutations affecting antigen presentation machinery can prevent immune recognition.
Host immune status: Patient-specific immune characteristics may influence treatment response.
Precision medicine approaches increasingly rely on multi-parameter biomarker strategies that combine genomic, transcriptomic, and immunological data. Rather than relying on a single biomarker, researchers are exploring integrated models that incorporate multiple biological signals to better predict treatment outcomes.
Clinical Implications for Precision Oncology
The integration of molecular biomarkers into immunotherapy decision-making has significant implications for clinical practice. Molecular testing is now frequently performed as part of routine cancer evaluation to guide treatment selection.
For example, testing for PD-L1 expression and MSI status has become standard practice in several cancer types. Comprehensive genomic profiling can also provide information about tumor mutational burden and other genomic alterations that may influence treatment response.
However, implementing precision immunotherapy strategies requires careful consideration of several factors:
Access to molecular testing: Not all healthcare systems have equal access to advanced genomic testing technologies.
Standardization of assays: Differences in laboratory methods can affect biomarker interpretation.
Clinical evidence: Continued research is needed to validate emerging biomarkers and establish standardized thresholds.
Addressing these challenges will be essential to ensure that biomarker-guided immunotherapy strategies are implemented effectively and equitably.
Future Directions
Combination Therapies
One promising area of research involves combination immunotherapy strategies. Some tumors resist checkpoint inhibitors because their microenvironment suppresses immune activity. Combining immunotherapy with other treatments may help overcome these barriers.
Potential combination strategies include:
Immunotherapy combined with targeted therapies
Checkpoint inhibitors combined with chemotherapy or radiation
Dual checkpoint inhibition (e.g., PD-1 plus CTLA-4 blockade)
Immunotherapy combined with cancer vaccines or adoptive cell therapies
These approaches aim to enhance immune activation while simultaneously modifying the tumor microenvironment to make tumors more susceptible to immune attack.
Artificial Intelligence and Biomarker Discovery
Advances in artificial intelligence (AI) and computational biology are also playing an increasing role in biomarker discovery. Machine learning algorithms can analyze large-scale datasets including genomic sequencing, imaging data, and clinical outcomes to identify patterns associated with treatment response.
AI-based models may help identify novel biomarkers or develop predictive frameworks that integrate multiple data types. For example, combining genomic profiles with tumor microenvironment characteristics and radiological imaging features could provide more comprehensive predictions of immunotherapy outcomes.
As biomedical datasets continue to grow in size and complexity, computational approaches will likely become increasingly important for translating molecular insights into clinical decision-making tools.
Conclusion
Immunotherapy represents one of the most significant advances in modern oncology, offering new treatment options for patients with diverse malignancies. However, the variability in patient responses highlights the importance of precision medicine approaches that guide treatment selection based on molecular and immunological characteristics.
Biomarkers such as PD-L1 expression, tumor mutational burden, and microsatellite instability have already transformed clinical decision-making in several cancer types. Continued research is expanding our understanding of the complex biological factors that determine immunotherapy response.
Future advances will likely involve integrated biomarker strategies, combination therapies, and AI-driven analytical tools. Together, these developments may improve patient selection, optimize treatment strategies, and enhance clinical outcomes.
For clinicians and healthcare leaders, understanding the evolving landscape of immunotherapy biomarkers is essential as precision oncology continues to shape the future of cancer care.
References
Topalian SL, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. New England Journal of Medicine.
Rizvi NA, et al. Cancer immunology: mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science.
Le DT, et al. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science.
Goodman AM, et al. Tumor mutational burden as an independent predictor of response to immunotherapy. Molecular Cancer Therapeutics.
Chan TA, et al. Development of tumor mutational burden as an immunotherapy biomarker. Annals of Oncology.
